{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:17:24Z","timestamp":1784557044745,"version":"3.55.0"},"reference-count":26,"publisher":"Bioscientifica","content-domain":{"domain":["edm.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,11,1]]},"abstract":"Summary<\/jats:title>\n A previously healthy 32-year-old woman developed cyclical mood swings after being prescribed cabergoline for a pituitary microprolactinoma. These mood swings persisted for over 2 years, at which point she developed an acute manic episode with psychotic features and was admitted to a psychiatry unit. Cabergoline was discontinued and replaced with aripiprazole 10\u200amg\/day. Her manic episode quickly resolved, and she was discharged within 6 days of admission. The aripiprazole suppressed her prolactin levels for over 18 months of follow-up, even after the dose was lowered to 2\u200amg\/day. There was no significant change in tumor size over 15 months, treatment was well tolerated. However, after 9 months of taking 2 mg aripiprazole, she developed brief manic symptoms, and the dose was returned to 10 mg daily, with good effect.<\/jats:p>\n \n Learning points<\/jats:title>\n \n \n \n Dopamine agonists such as cabergoline, which are a standard treatment for microprolactinomas, can have serious adverse effects such as psychosis or valvular heart disease.<\/jats:p>\n <\/jats:list-item>\n \n Aripiprazole is a well-tolerated atypical antipsychotic that, unlike other antipsychotics, is a partial dopamine agonist capable of suppressing prolactin levels.<\/jats:p>\n <\/jats:list-item>\n \n Adjunctive, low-dose aripiprazole has been utilized to reverse risperidone-induced hyperprolactinemia.<\/jats:p>\n <\/jats:list-item>\n \n This case report demonstrates how aripiprazole monotherapy, in doses ranging from 2 to 10\u200amg\/day, was effective in suppressing prolactin in a woman with a microprolactinoma who developed psychiatric side effects from cabergoline.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1530\/edm-15-0100","type":"journal-article","created":{"date-parts":[[2015,11,17]],"date-time":"2015-11-17T02:51:44Z","timestamp":1447728704000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-2","source":"Crossref","is-referenced-by-count":4,"title":["Management of a microprolactinoma with aripiprazole in a woman with cabergoline-induced mania"],"prefix":"10.1530","volume":"2015","author":[{"given":"Lisa","family":"Burback","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e3182456de7","article-title":"Hyperprolactinemia with aripiprazole understanding the paradox of","volume":"21","author":"GangadharBN","year":"2014","journal-title":"American Journal Therapeutics"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/JCP.0000000000000151","article-title":"Prolactin deficiency by aripiprazole","volume":"34","year":"2014","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"ref21","article-title":"Treating prolactinomas with dopamine agonists: always worth the gamble?","year":"2010","journal-title":"Endocrine"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2174\/156802608785161457","article-title":"Receptor-binding and pharmacokinetic properties of dopaminergic agonists","volume":"8","year":"2008","journal-title":"Current Topics in Medicinal Chemistry"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2174\/156802608785161457","article-title":"Receptor-binding and pharmacokinetic properties of dopaminergic agonists","volume":"8","year":"2008","journal-title":"Current Topics in Medicinal Chemistry"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/JCP.0b013e3181ca3c85","article-title":"Treatment with aripiprazole for hyperprolactinemia induced by pituitary microadenoma in a bipolar I disorder patient","volume":"30","year":"2010","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"ref01","first-page":"370","article-title":"Management of psychosis associated with a prolactinoma: case and review of the literature","volume":"51","year":"2015","journal-title":"Psychosomatics"},{"key":"ref131","first-page":"370","article-title":"Management of psychosis associated with a prolactinoma: case and review of the literature","volume":"51","year":"2015","journal-title":"Psychosomatics"},{"key":"ref31","first-page":"37","article-title":"First Manic Episode in a 55-Year-Old Man After Initiation of Aripiprazole","volume":"7","journal-title":"Psychiatry"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.psyneuen.2015.04.011","article-title":"Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: a randomized, double-blind, placebo-controlled, dose-response study","volume":"58","year":"2015","journal-title":"Psychoneuroendocrinology"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/JCP.0b013e3181ee832d","article-title":"Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia","volume":"30","year":"2010","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"ref231","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e3182456de7","article-title":"Hyperprolactinemia with aripiprazole understanding the paradox of","volume":"21","author":"GangadharBN","year":"2014","journal-title":"American Journal Therapeutics"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00213-013-3154-1","article-title":"A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder","volume":"228","year":"2013","journal-title":"Psychopharmacology"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"e70179","DOI":"10.1371\/journal.pone.0070179","article-title":"Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials","volume":"8","year":"2013","journal-title":"PLoS ONE"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1176\/appi.psy.50.4.317","article-title":"Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorigenic hyperprolactinemia","volume":"50","year":"2009","journal-title":"Psychosomatics"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00213-013-3154-1","article-title":"A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder","volume":"228","year":"2013","journal-title":"Psychopharmacology"},{"key":"ref151","article-title":"Treating prolactinomas with dopamine agonists: always worth the gamble?","year":"2010","journal-title":"Endocrine"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/JCP.0000000000000151","article-title":"Prolactin deficiency by aripiprazole","volume":"34","year":"2014","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"e70179","DOI":"10.1371\/journal.pone.0070179","article-title":"Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials","volume":"8","year":"2013","journal-title":"PLoS ONE"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/JCP.0b013e3181ca3c85","article-title":"Treatment with aripiprazole for hyperprolactinemia induced by pituitary microadenoma in a bipolar I disorder patient","volume":"30","year":"2010","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/JCP.0b013e3181ee832d","article-title":"Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia","volume":"30","year":"2010","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"ref171","first-page":"421","article-title":"The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review","volume":"28","year":"2014","journal-title":"CNS Drugs"},{"key":"ref41","first-page":"421","article-title":"The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review","volume":"28","year":"2014","journal-title":"CNS Drugs"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.psyneuen.2015.04.011","article-title":"Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: a randomized, double-blind, placebo-controlled, dose-response study","volume":"58","year":"2015","journal-title":"Psychoneuroendocrinology"},{"key":"ref161","first-page":"37","article-title":"First Manic Episode in a 55-Year-Old Man After Initiation of Aripiprazole","volume":"7","journal-title":"Psychiatry"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1176\/appi.psy.50.4.317","article-title":"Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorigenic hyperprolactinemia","volume":"50","year":"2009","journal-title":"Psychosomatics"}],"container-title":["Endocrinology, Diabetes & Metabolism Case Reports"],"original-title":[],"link":[{"URL":"https:\/\/edm.bioscientifica.com\/view\/journals\/edm\/2015\/1\/EDM15-0100.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/edm.bioscientifica.com\/downloadpdf\/journals\/edm\/2015\/1\/EDM15-0100.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:46:12Z","timestamp":1784555172000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/edm\/article\/3168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,1]]},"references-count":26,"URL":"https:\/\/doi.org\/10.1530\/edm-15-0100","relation":{},"ISSN":["2052-0573"],"issn-type":[{"value":"2052-0573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,1]]}}}